A Study of JNJ-87801493 in Combination With T-Cell Engagers in Participants With B-cell Non-Hodgkin Lymphoid (NHLs) Cancer
The purpose of this study is to characterize safety and to determine the recommended phase 2 regimen (RP2R) for JNJ-87801493 in combination with T-cell engagers (TCEs) \[Part A: Dose Escalation\] and to further assess the safety of JNJ-87801493 at the RP2R in combination with TCEs \[Part B: Dose Expansion\].
Lymphoma, Non-Hodgkin
DRUG: JNJ-87801493|DRUG: JNJ-80948543|DRUG: JNJ-75348780
Part 1: Number of Participants with Dose Limiting Toxicity (DLTs), Number of participants with DLTs will be reported. The DLTs are drug-related toxicities and are defined as any of the following: fatal toxicity, high grade non-hematologic toxicity, or hematologic toxicity, Up to 2 years 7 months|Part 1 and 2: Percentage of Participants with Adverse Events (AEs) by Severity, An AE is any untoward medical occurrence in a clinical study participant administered an investigational or non-investigational product and it does not necessarily have a causal relationship with the investigational product. Severity for AEs will be specified as per: NCI-CTCAE grades which are Grade 1 (mild), Grade 2 (moderate), Grade 3 (severe), Grade 4 (potentially life-threatening) and; American Society for Transplantation and Cellular Therapy (ASTCT) guidelines which is Grade 5 (death related to adverse event); Cytokine release syndrome (CRS) and associated neurologic toxicity events (immune effector cell-associated neurotoxicity syndrome events \[ICANS\])., Up to 2 years 7 months
Serum Concentration for JNJ-87801493, JNJ-80948543 and JNJ-75348780, Serum Concentration for JNJ-87801493, JNJ-80948543 and JNJ-75348780 will be reported., Up to 2 years 7 months|Area Under the Curve (AUCtau) for JNJ-87801493, JNJ-80948543 and JNJ-75348780, AUC tau is defined as area under the serum concentration-time curve during a dosing interval (tau).Area under the serum concentration curve (AUCtau) for JNJ-87801493, JNJ-80948543 and JNJ-75348780 will be reported., Up to 2 years 7 months|Maximum Serum Concentration (Cmax) for JNJ-87801493, JNJ-80948543 and JNJ-75348780, Maximum observed serum concentration (Cmax) for JNJ-87801493, JNJ-80948543 and JNJ-75348780 will be reported., Up to 2 years 7 months|Minimum Serum Concentration (Cmin) for JNJ-87801493, JNJ-80948543 and JNJ-75348780, Minimum observed serum concentration (Cmin) for JNJ-87801493, JNJ-80948543 and JNJ-75348780 will be reported., Up to 2 years 7 months|Area Under the Curve (AUC[0-t]) for JNJ-87801493, JNJ-80948543 and JNJ-75348780, Area under the curve from time zero to t (AUC\[0-t\]) for JNJ-87801493, JNJ-80948543 and JNJ-75348780 will be reported., Up to 2 years 7 months|Half-life (t1/2) for JNJ-87801493, JNJ-80948543 and JNJ-75348780, Half-life (t1/2) for JNJ-87801493, JNJ-80948543 and JNJ-75348780 will be reported., Up to 2 years 7 months|Time to Reach Cmax (Tmax) for JNJ-87801493, JNJ-80948543 and JNJ-75348780, Tmax is the time to reach maximum observed serum concentartion for JNJ-87801493, JNJ-80948543 and JNJ-75348780., Up to 2 years 7 months|Apparent Total Body Clearance (CL/F) for JNJ-87801493, JNJ-80948543 and JNJ-75348780, Apparent total body clearance (CL/F) for JNJ-87801493, JNJ-80948543 and JNJ-75348780 will be reported., Up to 2 years 7 months|Apparent Volume of Distribution (V/F) for JNJ-87801493, JNJ-80948543 and JNJ-75348780, Apparent volume of distribution (V/F) for JNJ-87801493, JNJ-80948543 and JNJ-75348780 will be reported., Up to 2 years 7 months|Number of Participants with Presence of Anti-JNJ-87801493, Anti-JNJ- 80948543 and Anti-JNJ-75348780 Antibodies, Number of participants with presence of antibodies binding to JNJ-87801493 or each combination partner (JNJ- 80948543 and JNJ-75348780)., Up to 2 years 7 months|Overall Response as Assessed by the Investigator, Overall response is defined as a best response of partial response (PR) or better., Up to 2 years 7 months|Complete Response (CR) as Assessed by the Investigator, Complete response (CR) is defined as a best response of CR., Up to 2 years 7 months|Very Good Partial Response (VGPR) or better for Waldenstr√∂m Macroglobulinemia (WM) Participants as Assessed by the Investigator, Very good partial response (VGPR) or better is defined as a best response of VGPR or better., Up to 2 years 7 months|Time to Response (TTR) as Assessed by the Investigator, Time to response (TTR) is defined for participants who achieve a response of PR or better as the time from the first dose of any study drug to the first response of PR or better., Up to 2 years 7 months|Duration of Response (DOR) as Assessed by the Investigator, Duration of response (DOR) is defined for participants who achieved a response of PR or better as the time from the first efficacy evaluation at which the participant meet all criteria for a response of PR or better to the date of first documented evidence of progressive disease or death., Up to 2 years 7 months
The purpose of this study is to characterize safety and to determine the recommended phase 2 regimen (RP2R) for JNJ-87801493 in combination with T-cell engagers (TCEs) \[Part A: Dose Escalation\] and to further assess the safety of JNJ-87801493 at the RP2R in combination with TCEs \[Part B: Dose Expansion\].